Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › FL › Miramar › NPI 1518903350
Lab

Quest Diagnostics Clinical Laboratories INC

Quest Diagnostics Clinical Laboratories INC was paid $197.58M by Medicaid between Jan 2018 and Dec 2024, across 599 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 5.8% of everything it billed.

33Billing provider infoQUEST DIAGNOSTICS CLINICAL LABORATORIES INC
MIRAMAR, FL 33025
33aNPI1518903350assigned 06/21/2006
33bProvider typeClinical Medical Laboratory
28Total paid$197.58M
24GClaims24,341,922
24DCodes billed599
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Florida

Rank by total paid#1 of 225
Median peer was paid$74K
This provider vs. median2,687×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official TIMMERMAN, LEAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$2.0M$4.0M$6.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018623,973$1.96M
20193,283,267$22.38M
20202,655,076$21.39M
20213,442,049$30.37M
20224,992,070$46.42M
20235,376,237$41.63M
2024incomplete3,969,250$33.43M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 5.8% 677,725 636,603 $11.49M
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 5.5% 135,259 123,806 $10.93M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 5.4% 30,004 28,585 $10.75M
80061 Lipid panel 4.8% 1,450,934 1,341,355 $9.41M
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 3.6% 27,025 25,687 $7.09M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 3.6% 670,545 629,729 $7.05M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 3.3% 507,400 462,225 $6.60M
84443 Thyroid stimulating hormone (TSH) 3.1% 1,060,799 970,676 $6.12M
80053 Comprehensive metabolic panel 2.8% 1,683,206 1,510,480 $5.58M
83036 Hemoglobin; glycosylated (A1C) 2.6% 972,518 893,728 $5.07M
86003 2.3% 97,808 85,307 $4.48M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 2.2% 1,634,249 1,476,626 $4.27M
587 more codes
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 2.1% 473,857 $4.15M
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 1.8% 200,015 $3.47M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1.7% 115,856 $3.43M
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.5% 167,841 $3.04M
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 1.4% 71,221 $2.83M
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 1.4% 150,302 $2.69M
87086 Culture, bacterial; quantitative colony count, urine 1.3% 577,249 $2.61M
87088 1.3% 352,948 $2.51M
80050 General health panel 1.3% 215,670 $2.49M
84439 1.2% 490,215 $2.45M
82728 1.1% 246,859 $2.22M
81229 1.1% 6,222 $2.16M
80074 <1% 67,125 $1.80M
86803 <1% 266,376 $1.80M
82746 <1% 236,206 $1.80M
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 31,335 $1.75M
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 18,600 $1.71M
80055 <1% 64,962 $1.63M
81513 <1% 31,859 $1.60M
86480 <1% 53,615 $1.51M
82607 <1% 318,173 $1.45M
87340 <1% 196,629 $1.42M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 50,210 $1.15M
87536 <1% 52,864 $1.09M
83655 <1% 141,884 $1.00M
82785 <1% 93,267 $958K
84403 <1% 91,457 $947K
81001 <1% 790,310 $859K
86235 <1% 47,240 $821K
82105 <1% 73,330 $816K
88142 <1% 57,079 $800K
81511 <1% 12,415 $800K
87070 <1% 194,412 $796K
87081 <1% 158,204 $795K
86038 <1% 92,645 $789K
84153 <1% 121,801 $783K
81443 <1% 1,697 $764K
87522 Neg quan hep c or qual rna <1% 34,327 $764K
36415 Collection of venous blood by venipuncture <1% 608,150 $702K
82670 <1% 48,545 $681K
80081 <1% 28,883 $680K
87209 <1% 52,699 $648K
86592 <1% 338,622 $644K
87799 <1% 62,513 $636K
85027 <1% 267,694 $595K
87186 <1% 158,304 $591K
84146 <1% 59,712 $591K
84702 <1% 95,644 $581K
87902 <1% 5,468 $581K
83001 <1% 72,011 $579K
82784 <1% 69,902 $561K
83970 <1% 46,462 $548K
86696 <1% 60,338 $538K
83550 <1% 214,116 $525K
82627 <1% 31,527 $523K
84481 <1% 67,257 $494K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 2,774 $483K
81329 <1% 14,183 $477K
83540 <1% 241,266 $466K
84402 <1% 45,476 $457K
86787 <1% 46,859 $451K
82570 <1% 291,868 $449K
86800 <1% 43,397 $426K
83002 <1% 65,544 $394K
83525 <1% 75,966 $379K
86364 <1% 28,445 $368K
87512 <1% 29,230 $355K
86360 <1% 36,645 $353K
85652 <1% 166,522 $350K
82652 <1% 27,418 $348K
86008 <1% 18,079 $342K
84480 <1% 65,966 $341K
87077 <1% 152,134 $326K
88141 <1% 31,470 $315K
82274 <1% 52,041 $313K
86695 <1% 56,200 $312K
86769 <1% 19,401 $311K
84436 <1% 151,842 $309K
82043 <1% 238,742 $300K
83020 <1% 51,827 $291K
80048 Basic metabolic panel (calcium, ionized) <1% 110,949 $289K
83735 <1% 81,347 $284K
84479 <1% 97,268 $280K
83013 <1% 19,791 $271K
80349 <1% 20,193 $269K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 6,899 $267K
88185 <1% 1,383 $264K
86140 <1% 150,997 $264K
83520 <1% 47,593 $261K
86376 <1% 62,245 $260K
88342 <1% 4,472 $251K
82465 <1% 69,663 $248K
86160 <1% 26,499 $247K
86147 <1% 16,297 $243K
86665 <1% 14,697 $241K
84144 <1% 28,707 $238K
87563 <1% 16,919 $236K
85660 <1% 44,289 $234K
86146 <1% 13,754 $230K
85730 <1% 87,334 $229K
82950 <1% 118,016 $226K
87901 <1% 3,161 $226K
86704 <1% 60,679 $218K
86706 <1% 58,057 $217K
82150 <1% 28,635 $209K
84681 <1% 17,934 $206K
80361 <1% 20,344 $205K
86762 <1% 34,658 $202K
82550 <1% 42,066 $201K
81243 <1% 14,411 $199K
86225 <1% 27,296 $196K
86780 <1% 33,768 $195K
82378 <1% 25,708 $191K
87631 <1% 4,807 $183K
86317 <1% 33,547 $182K
82951 <1% 28,516 $182K
87449 <1% 25,905 $177K
86850 <1% 36,947 $177K
86708 <1% 50,392 $170K
81596 <1% 5,521 $170K
84445 <1% 7,936 $165K
80348 <1% 11,150 $164K
88230 <1% 3,195 $162K
82533 <1% 18,003 $161K
83718 <1% 56,786 $159K
83615 <1% 39,332 $158K
80076 <1% 60,259 $158K
84305 <1% 15,183 $156K
83880 <1% 13,433 $156K
87506 <1% 1,965 $154K
87480 <1% 11,895 $148K
83516 <1% 37,692 $147K
86481 <1% 2,815 $143K
80365 <1% 20,020 $142K
83021 <1% 25,559 $140K
84550 <1% 108,979 $138K
83498 <1% 12,717 $134K
87177 <1% 52,577 $133K
82024 <1% 5,967 $131K
82947 <1% 46,314 $131K
83993 <1% 15,117 $130K
82672 <1% 11,496 $129K
80373 <1% 10,377 $129K
80346 <1% 11,723 $126K
86334 <1% 14,860 $123K
88262 <1% 3,161 $123K
87900 <1% 3,154 $120K
86200 <1% 28,650 $119K
84270 <1% 17,856 $119K
87660 <1% 13,213 $118K
85610 <1% 115,256 $114K
80354 <1% 10,458 $114K
82977 <1% 27,783 $112K
87529 <1% 4,695 $106K
80197 <1% 16,119 $106K
82677 <1% 9,757 $104K
86300 <1% 13,118 $103K
87147 <1% 58,698 $100K
87906 <1% 1,512 $100K
87427 <1% 32,750 $100K
86431 <1% 56,764 $98K
87338 <1% 22,442 $97K
85240 <1% 8,242 $96K
82248 <1% 75,099 $96K
87075 <1% 18,608 $93K
87205 <1% 26,480 $92K
84154 <1% 17,141 $92K
88341 <1% 1,719 $91K
86359 <1% 19,537 $91K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 14,894 $90K
80323 <1% 7,913 $90K
82085 <1% 5,991 $90K
87497 <1% 5,056 $89K
80358 <1% 10,701 $89K
84207 <1% 5,890 $87K
83690 <1% 36,455 $86K
87517 <1% 4,796 $86K
88312 <1% 1,554 $85K
80164 <1% 14,977 $85K
87045 <1% 34,871 $84K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 1,674 $83K
86255 <1% 19,680 $83K
86304 <1% 9,817 $82K
83521 <1% 5,086 $81K
82157 <1% 6,266 $81K
86644 <1% 5,780 $80K
86021 <1% 9,027 $80K
87329 <1% 22,508 $79K
84182 <1% 1,571 $78K
86039 <1% 26,393 $78K
84156 <1% 76,231 $76K
87046 <1% 16,386 $74K
81003 <1% 108,715 $74K
82103 <1% 4,697 $73K
81257 <1% 2,347 $71K
80324 <1% 6,812 $70K
80321 <1% 7,330 $69K
80069 <1% 25,868 $69K
87150 <1% 4,632 $68K
85246 <1% 8,006 $67K
84466 <1% 10,283 $65K
84425 <1% 8,900 $63K
86664 <1% 12,902 $62K
86336 <1% 9,875 $61K
86361 <1% 12,854 $60K
81512 <1% 2,182 $60K
86341 <1% 4,697 $60K
84703 <1% 22,871 $60K
80320 <1% 6,798 $60K
83921 <1% 7,921 $59K
81241 <1% 2,374 $59K
80356 <1% 6,134 $59K
86765 <1% 12,309 $58K
87510 <1% 11,875 $58K
80353 <1% 7,072 $58K
87481 <1% 10,271 $58K
88304 <1% 2,528 $57K
82330 <1% 7,566 $57K
86357 <1% 5,500 $56K
84100 <1% 46,909 $56K
82542 <1% 6,875 $56K
86355 <1% 6,228 $56K
86258 <1% 4,926 $55K
88112 <1% 2,263 $55K
85018 <1% 46,046 $54K
80362 <1% 6,465 $54K
85045 <1% 35,307 $54K
81401 <1% 592 $54K
80368 <1% 6,539 $53K
80337 <1% 6,222 $53K
85245 <1% 7,302 $52K
84165 <1% 20,666 $52K
85014 <1% 38,266 $52K
83992 <1% 7,185 $51K
85247 <1% 4,871 $49K
83090 <1% 15,042 $49K
86141 <1% 13,776 $49K
82653 <1% 2,953 $48K
86812 <1% 4,860 $48K
82626 <1% 2,997 $48K
82787 <1% 3,646 $48K
82140 <1% 7,883 $48K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 1,273 $48K
81025 <1% 6,836 $47K
80370 <1% 6,145 $47K
80377 <1% 5,685 $46K
80338 <1% 6,220 $45K
82088 <1% 3,074 $45K
86777 <1% 6,213 $45K
82139 <1% 3,119 $45K
84460 <1% 30,674 $45K
82668 <1% 4,243 $45K
86735 <1% 11,896 $45K
80345 <1% 8,272 $45K
88184 <1% 1,358 $44K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 537 $44K
88313 <1% 271 $44K
86335 <1% 2,685 $44K
87625 <1% 4,472 $44K
82247 <1% 22,371 $43K
86709 <1% 7,362 $43K
86900 <1% 32,578 $43K
86774 <1% 7,743 $43K
82565 <1% 27,807 $43K
80326 <1% 6,185 $42K
82040 <1% 15,988 $41K
85300 <1% 2,249 $40K
80359 <1% 3,529 $40K
80369 <1% 5,552 $40K
86301 <1% 6,459 $39K
81382 <1% 597 $39K
80363 <1% 4,577 $39K
87255 <1% 1,989 $39K
82310 <1% 19,632 $39K
86648 <1% 7,209 $38K
80177 <1% 7,036 $37K
80372 <1% 5,173 $37K
86870 <1% 6,257 $35K
84630 <1% 7,631 $35K
82525 <1% 4,578 $35K
80202 <1% 4,194 $35K
84450 <1% 26,327 $34K
83519 <1% 4,918 $34K
85060 <1% 4,217 $34K
86645 <1% 5,244 $34K
87535 <1% 2,155 $34K
82390 <1% 5,587 $34K
82657 <1% 2,663 $33K
86705 <1% 8,978 $32K
86381 <1% 3,888 $32K
81270 <1% 671 $32K
86162 <1% 5,744 $31K
80360 <1% 3,500 $30K
82731 <1% 1,354 $30K
80332 <1% 3,641 $29K
84134 <1% 4,866 $29K
81400 <1% 843 $29K
85613 <1% 8,003 $28K
80366 <1% 3,815 $28K
86060 <1% 4,646 $28K
88189 <1% 1,216 $28K
86747 <1% 1,956 $28K
82952 <1% 22,950 $27K
87324 <1% 9,593 $27K
83010 <1% 5,862 $27K
82610 <1% 4,169 $27K
86778 <1% 4,842 $27K
80339 <1% 4,177 $27K
86901 <1% 32,521 $26K
80374 <1% 2,874 $26K
84244 <1% 3,152 $26K
85306 <1% 2,745 $26K
84520 <1% 18,640 $25K
80178 <1% 5,988 $25K
80342 <1% 3,637 $24K
85379 <1% 4,650 $24K
81206 <1% 438 $24K
83003 <1% 2,110 $24K
84432 <1% 5,663 $24K
84482 <1% 1,903 $24K
84590 <1% 4,075 $23K
80329 <1% 4,287 $22K
86618 <1% 2,863 $22K
87101 <1% 5,075 $22K
82164 <1% 3,806 $22K
81376 <1% 425 $21K
81240 <1% 1,653 $21K
80156 <1% 2,478 $21K
84075 <1% 13,994 $21K
82379 <1% 2,686 $21K
84080 <1% 1,575 $21K
85041 <1% 21,517 $21K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 2,196 $21K
81291 <1% 712 $21K
87662 <1% 1,086 $21K
86337 <1% 2,133 $20K
87350 <1% 2,841 $20K
86617 <1% 1,804 $20K
82107 <1% 948 $19K
84155 <1% 17,540 $19K
82172 <1% 4,150 $19K
84478 <1% 8,616 $19K
86015 <1% 4,481 $19K
87040 <1% 3,138 $19K
80175 <1% 3,436 $18K
82104 <1% 2,085 $18K
83835 <1% 2,059 $18K
82530 <1% 2,253 $18K
85303 <1% 2,613 $18K
86231 <1% 2,318 $17K
81361 <1% 629 $17K
87493 <1% 1,686 $17K
81205 <1% 400 $17K
80357 <1% 2,453 $17K
80367 <1% 1,874 $17K
86611 <1% 2,283 $16K
86593 <1% 14,811 $16K
80364 <1% 1,871 $16K
87102 <1% 3,962 $16K
80299 <1% 1,957 $16K
84166 <1% 3,615 $16K
83918 <1% 1,726 $16K
80333 <1% 1,862 $15K
81364 <1% 123 $15K
83014 <1% 8,509 $15K
82679 <1% 1,382 $15K
87425 <1% 2,029 $15K
82747 <1% 1,624 $15K
85384 <1% 2,397 $15K
82175 <1% 1,474 $15K
83883 <1% 5,583 $14K
86738 <1% 1,767 $14K
82232 <1% 3,126 $14K
83605 <1% 2,059 $14K
80340 <1% 1,857 $14K
86880 <1% 2,547 $14K
86682 <1% 1,846 $14K
82955 <1% 2,274 $14K
86308 <1% 2,913 $14K
80183 <1% 2,399 $14K
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 8,081 $13K
80344 <1% 1,874 $13K
83695 <1% 4,586 $13K
84446 <1% 2,639 $13K
86001 <1% 2,794 $13K
0346U <1% 412 $12K
83631 <1% 1,483 $12K
82397 <1% 3,032 $12K
81479 Unlisted molecular pathology procedure <1% 760 $12K
80051 <1% 6,380 $12K
82985 <1% 4,803 $12K
83721 <1% 8,395 $11K
82340 <1% 2,711 $11K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 1,744 $11K
86684 <1% 2,406 $11K
85598 <1% 1,512 $11K
82166 <1% 692 $11K
86036 <1% 4,297 $11K
86671 <1% 2,911 $11K
81255 <1% 419 $11K
80159 <1% 1,898 $10K
80185 <1% 1,814 $10K
80330 <1% 2,280 $10K
87076 <1% 3,971 $10K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 783 $10K
81250 <1% 533 $10K
81279 <1% 218 $10K
82384 <1% 827 $10K
87206 <1% 4,702 $10K
83704 <1% 1,582 $10K
86161 <1% 1,496 $10K
80235 <1% 808 $9K
83698 <1% 1,350 $9K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 130 $9K
81381 <1% 325 $9K
81015 <1% 8,914 $9K
81251 <1% 419 $9K
81200 <1% 498 $9K
81330 <1% 417 $8K
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 4,839 $8K
89055 <1% 2,862 $8K
83625 <1% 1,705 $8K
84597 <1% 745 $8K
83825 <1% 1,613 $8K
84132 <1% 4,301 $8K
85004 <1% 2,337 $8K
82507 <1% 523 $8K
80145 <1% 521 $8K
82239 <1% 971 $8K
80162 <1% 1,091 $8K
87185 <1% 4,043 $8K
84376 <1% 2,529 $7K
80195 <1% 1,357 $7K
87800 <1% 383 $7K
86702 <1% 2,828 $7K
81290 <1% 403 $7K
84295 <1% 5,297 $7K
84255 <1% 635 $7K
84238 <1% 354 $7K
81209 <1% 494 $7K
85007 <1% 6,626 $7K
87328 <1% 1,310 $7K
81260 <1% 480 $7K
87650 <1% 588 $7K
81242 <1% 413 $7K
86794 <1% 646 $6K
84210 <1% 928 $6K
82705 <1% 2,037 $6K
86148 <1% 2,137 $6K
80165 <1% 1,068 $6K
82017 <1% 1,112 $6K
87521 Neg quan hep c or qual rna <1% 392 $6K
86343 <1% 907 $6K
87107 <1% 1,619 $6K
86707 <1% 1,642 $6K
86340 <1% 843 $6K
82374 <1% 4,409 $6K
83630 <1% 665 $6K
85049 <1% 3,991 $6K
84484 <1% 1,345 $6K
81256 <1% 190 $6K
82435 <1% 4,570 $6K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 154 $5K
84143 <1% 629 $5K
85302 <1% 702 $5K
85048 <1% 4,575 $5K
86886 <1% 2,984 $5K
82575 <1% 1,377 $5K
80355 <1% 1,763 $5K
83935 <1% 1,605 $5K
87467 <1% 458 $5K
85250 <1% 674 $5K
87106 <1% 1,543 $5K
86631 <1% 680 $5K
86256 <1% 1,286 $4K
85597 <1% 800 $4K
87220 <1% 3,262 $4K
81374 <1% 107 $4K
87807 <1% 866 $4K
86701 <1% 2,823 $4K
80184 <1% 689 $4K
85305 <1% 950 $4K
83986 <1% 1,411 $4K
80335 <1% 482 $4K
84300 <1% 2,977 $4K
87116 <1% 874 $4K
83527 <1% 557 $4K
82180 <1% 954 $3K
85230 <1% 454 $3K
87254 <1% 262 $3K
86790 <1% 594 $3K
84252 <1% 452 $3K
83930 <1% 1,106 $3K
84140 <1% 406 $3K
82642 <1% 277 $3K
85270 <1% 477 $3K
87272 <1% 898 $2K
82523 <1% 668 $2K
81339 <1% 78 $2K
81207 <1% 55 $2K
84133 <1% 1,630 $2K
86905 <1% 1,963 $2K
82552 <1% 377 $2K
86663 <1% 331 $2K
80201 <1% 399 $2K
86632 <1% 618 $2K
82308 <1% 173 $2K
87015 <1% 1,234 $2K
83945 <1% 459 $2K
88307 <1% 14 $2K
87230 <1% 260 $2K
87184 <1% 717 $2K
80203 <1% 229 $2K
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 8,325 $2K
82365 <1% 234 $1K
81219 <1% 47 $1K
84560 <1% 1,043 $1K
88271 <1% 58 $1K
85670 <1% 321 $1K
81517 <1% 15 $1K
84433 <1% 56 $1K
81269 <1% 13 $1K
85280 <1% 167 $1K
85301 <1% 250 $1K
86041 <1% 152 $979.19
84163 <1% 415 $960.50
G0124 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician <1% 70 $951.68
80503 <1% 86 $951.41
80158 <1% 107 $946.35
84442 <1% 158 $932.93
82681 <1% 105 $901.39
82671 <1% 42 $894.03
80371 <1% 88 $865.27
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 25 $847.00
82656 <1% 251 $792.08
G0475 Hiv antigen/antibody, combination assay, screening <1% 148 $786.41
G0476 Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test <1% 41 $780.12
86316 <1% 135 $779.90
86215 <1% 104 $763.09
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 1,178 $755.63
88289 <1% 76 $695.98
87999 <1% 191 $679.10
84585 <1% 111 $676.59
84378 <1% 265 $668.98
84105 <1% 456 $660.54
87634 <1% 42 $639.07
87300 <1% 38 $565.62
80230 <1% 27 $551.21
81508 <1% 75 $535.78
81332 <1% 27 $529.27
80168 <1% 62 $497.07
82010 <1% 111 $493.21
86382 <1% 12 $429.20
84591 <1% 59 $376.08
87581 <1% 28 $338.86
85651 <1% 346 $338.24
82540 <1% 107 $316.75
89060 <1% 258 $296.14
86023 <1% 20 $285.71
82261 <1% 74 $270.62
87140 <1% 131 $249.51
84392 <1% 160 $249.27
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision <1% 500 $246.79
86606 <1% 33 $233.63
86362 <1% 31 $231.78
83018 <1% 13 $224.25
82941 <1% 63 $188.81
82634 <1% 17 $180.41
89051 <1% 241 $173.87
82436 <1% 88 $172.05
87207 <1% 103 $147.53
83919 <1% 34 $132.95
82978 <1% 27 $118.58
86710 <1% 16 $99.25
86615 <1% 13 $92.22
86043 <1% 15 $89.03
83497 <1% 12 $82.88
86042 <1% 15 $81.58
86609 <1% 19 $80.89
85307 <1% 12 $63.77
86022 <1% 20 $54.34
G0306 Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count <1% 811 $53.51
82595 <1% 35 $52.32
82131 <1% 14 $49.70
G0307 Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) <1% 844 $19.80
86999 <1% 143 $6.21
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 67 $2.07

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTIMMERMAN, LEAH (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Same official

Other billing entities under TIMMERMAN, LEAH

Full network →
ProviderLocationPaid
Unilab CorporationWest Hills, CA$668.50M
Quest Diagnostics IncorporatedClifton, NJ$637.74M
Quest Diagnostics LLC IlWood Dale, IL$429.84M
Quest Diagnostics Clinical Laboratories INCIrving, TX$276.76M
Labone LLCLenexa, KS$212.28M
Quest Diagnostics Clinical Laboratories INCTucker, GA$211.13M
Labone of Ohio INCCincinnati, OH$167.17M
Unilab CorporationSacramento, CA$141.24M
Quest Diagnostics Incorporated MDBaltimore, MD$121.81M
Quest Diagnostics IncorporatedLas Vegas, NV$59.32M
Quest Diagnostics LLC IlSchaumburg, IL$50.71M
Quest Diagnostics Clinical Laboratories INCTampa, FL$49.99M
Quest Diagnostics Nichols Institute, INC.Chantilly, VA$46.91M
Quest Diagnostics Nichols InstituteSan Juan Capistrano, CA$39.93M
Quest Diagnostics Clinical Laboratories INCNorristown, PA$22.72M
Specialty Laboratories INCWest Hills, CA$16.76M
Quest Diagnostics Clinical Laboratories INCDenver, CO$14.27M
Quest Diagnostics Clinical Laboratories INCHouston, TX$8.76M
Med Fusion, LLCLewisville, TX$4.17M
Quest Diagnostics Clinical Laboratories INCMaryland Heights, MO$2.98M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.